Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Net Income towards Common Stockholders: 2011-2025

Historic Net Income towards Common Stockholders for Adma Biologics (ADMA) over the last 12 years, with Sep 2025 value amounting to $36.4 million.

  • Adma Biologics' Net Income towards Common Stockholders rose 1.45% to $36.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $202.1 million, marking a year-over-year increase of 275.18%. This contributed to the annual value of $197.7 million for FY2024, which is 800.00% up from last year.
  • According to the latest figures from Q3 2025, Adma Biologics' Net Income towards Common Stockholders is $36.4 million, which was up 35.40% from $26.9 million recorded in Q2 2025.
  • In the past 5 years, Adma Biologics' Net Income towards Common Stockholders ranged from a high of $111.9 million in Q4 2024 and a low of -$18.8 million during Q2 2021.
  • Moreover, its 3-year median value for Net Income towards Common Stockholders was $17.8 million (2024), whereas its average is $22.3 million.
  • In the last 5 years, Adma Biologics' Net Income towards Common Stockholders tumbled by 49.63% in 2023 and then skyrocketed by 1,299.96% in 2024.
  • Over the past 5 years, Adma Biologics' Net Income towards Common Stockholders (Quarterly) stood at -$16.5 million in 2021, then climbed by 28.55% to -$11.8 million in 2022, then plummeted by 49.63% to -$17.6 million in 2023, then soared by 734.15% to $111.9 million in 2024, then climbed by 1.45% to $36.4 million in 2025.
  • Its Net Income towards Common Stockholders stands at $36.4 million for Q3 2025, versus $26.9 million for Q2 2025 and $26.9 million for Q1 2025.